Lv1
40 积分 2025-08-18 加入
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease
1个月前
已完结
Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers
1个月前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
1个月前
已完结
A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers
1个月前
已关闭
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial
1个月前
已完结
Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer
1个月前
已完结
Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies
1个月前
已关闭
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic
1个月前
已完结
Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors
2个月前
已完结
A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies
2个月前
已完结
皖公网安备34019202002308
